Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia

Current Oncology Reports - United States
doi 10.1007/s11912-018-0669-y
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group

Cancer
Cancer ResearchOncology
2018English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access
2017English

Short Overview on the Current Treatment of Chronic Myeloid Leukemia in Chronic Phase

Memo - Magazine of European Medical Oncology
OncologyHematology
2016English

Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation
2016English

Management of Chronic Myeloid Leukemia With BCR/ABL Inhibitors: Current Status and Future Perspectives

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2010English

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2019English

European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2020English

Current Patient Management of Chronic Myeloid Leukemia in Latin America

Cancer
Cancer ResearchOncology
2010English

Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal of Haematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy